Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

CGRP as the target of new migraine therapies - successful translation from bench to clinic

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Calcitonin gene-related peptide - beyond migraine prophylaxis

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Ageing as a risk factor for neurodegenerative disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Post-traumatic headache: epidemiology and pathophysiological insights

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Does inflammation have a role in migraine?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. The current role of MRI in differentiating multiple sclerosis from its imaging mimics

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Loss of retinal tension and permanent decrease in retinal function: a new porcine model of rhegmatogenous retinal detachment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects. CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. As these drugs come into clinical use, we provide an overview of knowledge that has led to successful development of these drugs. We describe the biology of CGRP signalling, summarize key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system. Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiology of migraine.

OriginalsprogEngelsk
TidsskriftNature reviews. Neurology
Vol/bind14
Udgave nummer6
Sider (fra-til)338-350
Antal sider13
ISSN1759-4758
DOI
StatusUdgivet - 2018

ID: 54579877